Please assess the completion status of the following clinical trial:

Trial Title: Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer~  * Metastatic disease~    * Patients with only bone metastases are not eligible~* Refractory disease, defined as disease progression, drug-related adverse reaction, or disease relapse during or within 12 months after completion of paclitaxel or docetaxel AND doxorubicin or epirubicin administered in the neoadjuvant, adjuvant, or metastatic setting~  * Total neoadjuvant or adjuvant taxane dose \> 700 mg/m\^2 for paclitaxel or \> 240 mg/m\^2 for docetaxel~ * Total taxane dose \> 350 mg/m\^2 for paclitaxel or \> 120 mg/m\^2 for docetaxel in the metastatic setting~ * Total neoadjuvant or adjuvant anthracycline dose \> 240 mg/m\^2 for doxorubicin or epirubicin~ * Total anthracycline dose \> 120 mg/m\^2 for doxorubicin or epirubicin in the metastatic setting~* HER2/neu overexpression~  * 3+ by immunohistochemistry or positive by fluorescence in situ hybridization~* No symptomatic brain metastases~* No pleural or pericardial effusion or ascites~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age~* 20 to 75~Sex~* Female~Menopausal status~* Not specified~Performance status~* ECOG 0-2~Life expectancy~* At least 3 months~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9.0 g/dL~Hepatic~* SGOT or SGPT ≤ 2.0 times upper limit of normal (ULN) (\< 3.0 times ULN for patients with liver metastases)~* Alkaline phosphatase ≤ 2.5 times ULN~* Bilirubin ≤ 1.5 mg/dL~Renal~* Creatinine ≤ 1.2 mg/dL~Cardiovascular~* LVEF \> 50%~Pulmonary~* No interstitial pneumonia with pulmonary fibrosis~Other~* No history of hypersensitivity reactions~* No serious, uncontrolled infection~* No other malignancy~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Prior trastuzumab (Herceptin®) for metastatic disease allowed~Chemotherapy~* See Disease Characteristics~* No prior capecitabine~* At least 2 weeks since prior antimetabolites for metastatic disease~* At least 4 weeks since prior alkylating agents, carcinostatic antibiotics, or other carcinostatic agents~Endocrine therapy~* At least 4 weeks since prior goserelin or leuprolide for metastatic disease~* At least 2 weeks since prior oral endocrine agents for metastatic disease~* No concurrent endocrine therapy~Radiotherapy~* No prior radiotherapy to target lesions~* At least 4 weeks since prior radiotherapy~* No concurrent radiotherapy, including radiotherapy for brain metastases~Surgery~* Not specified~Other~* Concurrent bisphosphonates for bone metastases allowed

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).